clinical diagnosis News
-
How Willem Einthoven gave doctors a window on the heart
If the doctor has ever placed electrodes on the skin to record a trace of a heartbeat, then thanks to this gentleman - Willem Einthoven. His invention, the electrocardiogram IECG), has been used for over 100 years and is still one of the most commonly used diagnostic tools in medicine. He became interested in electrical heart activity after watching a demonstration of a raw electrocardiogram ...
-
AioCare uses AI algorithm to automatically detect the cough during the spirometry examination.
AioCare’s R&D team has created an AI algorithm for automatic detection of cough during spirometry testing. It was possible thanks to using neural networks and machine learning technology. The article has been published in the Informatics in Medicine Unlocked. To build the algorithm a considerable data set (about 20,000 spirometry records) was used, obtaining 93% detection accuracy. It ...
By AioCare
-
Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder
Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration with Rhythm and today’s announcement of the ...
By Camurus AB
-
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
January 20, 2022 at 8:00 AM EST NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 20, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug ...
-
GutFlora Omics Platform Releases Total RNA Sequencing Service
GutFlora Omics Platform belongs to Creative Proteomics. With more than 10 years of experience in providing advanced multi-omics services, GutFlora Omics Platform offers services and support to customers through comprehensive intestinal flora research solutions. The product manager has recently announced total RNA sequencing service, which can be applied for the identification of key genes and for ...
-
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 18, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum’s SACT-1 repurposed drug for the ...
-
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Sep. 15, 2021-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has received clearance from the US FDA regarding the ...
-
JAMA Highlights Success of BrainScope`s EEG-based Concussion Index As Reliable Indicator of Concussion
JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion Index, to indicate the likelihood and severity of concussive brain injury and to aid in evaluating an athlete's readiness to return to play. "What ...
-
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
May 2, 2022 at 8:00 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--May 2, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug ...
-
CD Genomics’ RNA-Solutions Platform Now Supports Exosomal RNA Research
CD Genomics’ RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Based on rich RNA project experience and leading bioinformatics analytical capabilities, CD Genomics has launched a systematic solution for exosomal RNA research that assists in in-depth identification and functional analysis of exosomal ...
By CD Genomics
-
Classification and Biological Functions of Glycoproteins
Glycoprotein is a protein containing oligosaccharide chains that are covalently linked to each other. The oligosaccharide chains are usually linked to the protein by glycosylation. Glycoproteins are commonly found in animals, plants and microorganisms, with a wide variety of species and functions. They can be classified into three categories: 1. Soluble glycoproteins, which exist in ...
-
T,C&A Lab Declares Capability of Biomedical Materials Testing
Since the last few decades, biomedical materials have been extensively used in a lot of medical applications, such as tissue scaffolds, wound care, regenerative dentistry, bone graft, implantable devices and cosmetic surgery. Earlier this month, T,C&A Lab, a branch of Alfa Chemistry, announces to provide biomedical material testing service for customers worldwide who would like to ensure ...
-
Creative Proteomics Accelerates Life Science Research Through Mass Spectrometry Platform
Creative Proteomics, experienced proteomics, metabolomics, and bioinformatics services supplier, has been well equipped with advanced technologies to meet the increasing needs of researchers and scientists in their proteomics and metabolomics related researches. In the past few years, the technology of mass spectrometry has been greatly developed and their applications broadened. Based on more ...
-
Kidney and Pancreas Function Diagnostic Enzymes Are Now Available at Creative Enzymes
Creative Enzymes, a global leader in diagnostic enzyme manufacturing and supply, is dedicated to offering a wide range of enzyme products as well as customized enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched kidney and pancreas function diagnostic enzymes for the global market. The primary function of the kidney is to eliminate waste and excess ...
-
BrainScope Receives $4.5 Million Department of Defense Contract to Add Ocular Assessment to Future Concussion Products
BrainScope today announced that it has been awarded a research contract by the United States Department of Defense (DOD) valued at $4.5 million to create and integrate ocular capabilities into its handheld, multi-parameter mild Traumatic Brain Injury (mTBI) and concussion products. BrainScope’s initial product in the market, BrainScope One, is the first FDA-cleared medical device to offer ...
-
Forest Devices Announces Positive Study Results For Their Stroke Detection Technology
Medical technology pioneer Forest Devices, Inc. (FDI) today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive (LVO) strokes in emergency departments in the American Heart Association Journal, STROKE. LVOs are the type of ischemic stroke that require an interventional thrombectomy, only ...
-
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced today that its Phase 2, INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19 met its primary objective of safety. All efficacy ...
-
C2N Diagnostics Statement on FDA Accelerated Approval of Aducanumab forAlzheimer’s Treatment
C2N Diagnostics says the U.S. Food and Drug Administration’s (FDA) decision granting accelerated approval to aducanumab (Aduhelm) on the basis of amyloid plaque reduction for Alzheimer’s treatment represents a significant change in the ongoing fight against the horrible disease. Dr. Joel Braunstein, C2N’s CEO, said, “The accelerated approval of aducanumab will offer a ...
-
Acurable launches groundbreaking technology to diagnose sleep apnoea remotely
Acurable, a fast-growing medical device company, has announced the availability of its first product, AcuPebble SA100, a small wearable device which for the first time enables a fully automated and remote diagnosis of obstructive sleep apnoea (OSA). Traditionally, the diagnosis of OSA has required multiple hospital visits for patients, and doctors have had to manually review and analyse data from ...
-
Agilent Technologies to Collaborate with University of Queensland on Oral Cancer Research
Agilent Technologies Inc. (NYSE: A) today announced it will collaborate with the University of Queensland Centre for Clinical Research in Brisbane, Australia, to increase understanding of the genomic differences between young and older patients with oral cancer and between progressive and non-progressive oral potentially malignant lesions. Oral cancer is part of a group of cancers commonly ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you